NCT03814252View on ClinicalTrials.gov

Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2028

Conditions
Localized Prostate Cancer
Interventions
DEVICE

MRI-TULSA

"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"

Trial Locations (1)

Unknown

Department of Urology, VSSHP, University of Turku, Turku

All Listed Sponsors
lead

Turku University Hospital

OTHER_GOV

NCT03814252 - Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer | Biotech Hunter | Biotech Hunter